Literature DB >> 22104002

Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment.

Adriana Toro1, Elia Pulvirenti, Filippo Palermo, Isidoro Di Carlo.   

Abstract

BACKGROUND: Aim of this work was to compare quality of life (QoL) of patients affected by HCC and submitted to hepatic resection (HR), transarterial chemoembolization (TACE), radiofrequency ablation (RFA), or no treatment (NT).
METHODS: Patients affected by HCC between 2001 and 2009 were considered for this study. Gender, diabetes, hepatitis status, Child grade, tumor size, and recurrence were analyzed. QoL was assessed before treatment and 3, 6, 12, and 24 months after, using a FACT-Hep questionnaire. P value was considered significant if <0.01 and highly significant if <0.001.
RESULTS: Fourteen patients (27.45%) were treated with HR, 15 patients (29.41%) underwent TACE, RFA was performed in 9 patients (17.65%), and 13 patients (25.49%) were not treated. Physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns 24 months after HR were significantly higher compared to all other treatments.
CONCLUSIONS: Hepatic resection provides the best QoL at 24 months. RFA provides a worse QoL compared to HR, but a higher QoL compared to TACE or NT.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22104002     DOI: 10.1016/j.suronc.2011.10.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  27 in total

1.  Correct indication for surgery can prevent postoperative ascites in cirrhotic patients affected by hepatocellular carcinoma.

Authors:  Isidoro Di Carlo; Adriana Toro
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

2.  Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma.

Authors:  Cyrill Wehling; Daniel Hornuss; Pasquale Schneider; Christoph Springfeld; Katrin Hoffmann; De-Hua Chang; Patrick Naumann; Markus Mieth; Thomas Longerich; Clemens Kratochwil; Arianeb Mehrabi; Annika Gauss; Karl Heinz Weiss; Jan Pfeiffenberger
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-19       Impact factor: 4.553

3.  The quality of life after surgery for HCC can support the choice of this treatment.

Authors:  I Di Carlo; A Toro
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

4.  The extent of hepatectomy does not affect physical QOL in patients with HCC: reply.

Authors:  Yoshihiro Mise; Norihiro Kokudo
Journal:  World J Surg       Date:  2014-11       Impact factor: 3.352

5.  Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.

Authors:  Wei-Chu Chie; Fang Yu; Mengqian Li; Lorena Baccaglini; Jane M Blazeby; Chin-Fu Hsiao; Herng-Chia Chiu; Ronnie T Poon; Naoko Mikoshiba; Gillian Al-Kadhimi; Nigel Heaton; Jozer Calara; Peter Collins; Katharine Caddick; Anna Costantini; Valerie Vilgrain; Chieh Chiang
Journal:  Qual Life Res       Date:  2015-05-06       Impact factor: 4.147

6.  Assessment of complications after liver surgery: Two novel grading systems applied to patients undergoing hepatectomy.

Authors:  Li-Ning Xu; Bo Yang; Gui-Ping Li; De-Wei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

Review 7.  Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.

Authors:  Gino Boily; Jean-Pierre Villeneuve; Luc Lacoursière; Prosanto Chaudhury; Félix Couture; Jean-François Ouellet; Réal Lapointe; Stéphanie Goulet; Normand Gervais
Journal:  HPB (Oxford)       Date:  2014-06-24       Impact factor: 3.647

Review 8.  Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series.

Authors:  Michael E Egger; Joanna M Ohlendorf; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

9.  Psychometric properties of a brief, clinically relevant measure of pain in patients with hepatocellular carcinoma.

Authors:  Zeeshan Butt; Jin-Shei Lai; Jennifer L Beaumont; Karen Kaiser; Rajiv Mallick; David Cella; Jennifer L Steel
Journal:  Qual Life Res       Date:  2014-04-20       Impact factor: 4.147

10.  Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC.

Authors:  K J Hartrumpf; S Marquardt; T Werncke; T Murray; M M Kirstein; A Vogel; F Wacker; T Rodt
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-14       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.